Premium
Racial Differences in Blood Pressure Response to Angiotensin‐Converting Enzyme Inhibitors in Children: A Meta‐Analysis
Author(s) -
Li JS,
BakerSmith CM,
Smith PB,
Hasselblad V,
Murphy MD,
Califf RM,
Benjamin DK
Publication year - 2008
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2008.113
Subject(s) - natriuresis , angiotensin converting enzyme , blood pressure , bradykinin , vasodilation , medicine , angiotensin ii , pharmacology , clinical pharmacology , endocrinology , renin–angiotensin system , cardiology , receptor
Angiotensin‐converting enzyme (ACE) inhibitors are frequently used to treat hypertension in children. 1 ACE inhibitors alter the balance between the vasoconstrictive, salt‐retentive, and cardiac hypertrophic properties of angiotensin II and the vasodilatory and natriuretic properties of bradykinin; they also alter the metabolism of other vasoactive substances. 2 Through these mechanisms, ACE inhibitors decrease systemic vascular resistance and promote natriuresis without increasing heart rate. This study evaluated the results of six trials of ACE inhibitors in children, using meta‐analytic techniques to estimate the effect of race on blood pressure response. Clinical Pharmacology & Therapeutics (2008); 84 , 3, 315–319 doi: 10.1038/clpt.2008.113